omniture
logo
Search
CanariaBio Inc.
Media Room

Latest News

rss

CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer

SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnolog...

2024-08-23 20:00 4625

CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma...

2023-10-10 12:00 1616

CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer

The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this...

2023-08-21 20:00 1813
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer